The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested

Ulukaya, Engin; Ozdikicioglu, Ferda; Oral, Arzu Yilmaztepe; Demirci, Meral

doi:10.1016/j.tiv.2007.08.006

Cited by 166 publications

(115 citation statements)

References 27 publications

Supporting

Mentioning

113

Contrasting

Order By: Relevance

“…Therefore, it was suggested to use different methods in combination to assess cytotoxicity. 31 Selective cytotoxic effect of Anatolian M. lebetina obtusa against various cancer cell lines (not including leukemia) has been reported previously 26 and shown to be po- 26,30 Therefore, the cytotoxic potency of the venom on various cancer cell lines should be determined by an initial screening study. It has been reported that crude venom of M. lebetina (subspecies could be assigned as M. lebetina turanica, according the origin of the samples stated in the paper) inhibited the viability of K562 cells about 10% after treating with 50 µg/mL of venom for 72 h. 19 According to our results, M. l. obtusa venom was more potent on K562 cells, compared to M. l. turanica venom.…”

Section: Discussionmentioning

confidence: 96%

In Vitro Cytotoxic and Proapoptotic Activities of Anatolian Macrovipera Lebetina Obtusa (Dwigubski, 1832) Crude Venom on Cultured K562 Human Chronic Myelogenous Leukemia Cells.

Süzergöz¹

2016

UHOD

View full text Add to dashboard Cite

In the context of searching for anticancer compounds in natural products, snake venom is one of the important sources for peptide/ protein based bioactive molecules. Proteins and peptides with anticancer activity were purified and identified from snake venoms. The aim of the present study was to determine the in vitro cytotoxicity of Macrovipera lebetina obtusa (Blunt-Nosed Viper) crude venom from southeastern Anatolia against K562 human chronic myelogenous leukemia (CML) cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and Adenosine tripohsphate (ATP) assays. Additionally, the apoptosis induction was assessed by morphological evaluation and immunohistochemical analysis for activated caspase-3. For histopahtological evaluation, haematoxylineosin, giemsa and papanicolau stains were used in combination. M. l. obtusa venom showed dose-dependent toxicity against K562 cells after 72 h treatment with different concentrations of crude venom. IC50 values were 0.45 and 0.37 µg/mL for MTT and ATP assays, respectively. Nuclear fragmentation and condensation, apoptotic bodies and activation of caspase-3, as an induction of apoptosis were also observed in K562 cells. Since apoptosis-inducing compounds are important for the treatment of cancer, further studies on Anatolian M. l. obtusa venom could result in the purification and identification of new proteins and peptides, which might have therapeutic value for the treatment of CML. Keywords: Anticancer, Apoptosis, Blunt-nosed viper, Macrovipera lebetina obtusa, Snake venom ÖZET Anadolu'da Yayılış Gösteren Macrovipera lebetina obtusa (Dwigubski, 1832) Zehrinin K562 İnsan Kronik Myeloid Lösemi Hücreleri Üzerinde in vitro Sitotoksik ve Apoptotik Aktiviteleri Doğal ürünlerde antikanser bileşiklerin araştırılması kapsamındaki çalışmalarda kullanılan önemli biyoaktif peptit/protein kaynaklarından biri de yılan zehridir. Yılan zehirlerinden antikanser etkili protein ve peptitler saflaştırılmış ve tanımlanmıştır. Bu çalışmanın amacı, güneydoğu Anadolu bölgesinde bulunan Macrovipera lebetina obtusa (Koca Engerek) ham zehrinin K562 insan kronik myeloid lösemi (KML) hücreleri üzerinde in vitro sitotokik etkisinin 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) ve Adenosine tripohsphate (ATP) testleri ile belirlenmesidir. Ek olarak, morfolojik değerlendirme ve aktif kaspaz-3 immünohistokimyasal analizi ile zehrin apoptotik etkisi de değerlendirilmiştir. Histopatolojik değerlendirme için hematoksilen-eozin, gimza ve papanikolau boyaları kullanılmıştır. M. l. obtusa zehrinin farklı konsantrasyonlarıyla 72 saatlik inkübasyon sonucunda K562 hücrelerine karşı doza bağlı toksisite görülmüştür. IC50 değerleri MTT ve ATP testleriyle sırasıyla 0.45 and 0.37 µg/mL olarak hesaplanmıştır. Ayrıca apoptoz uyarımının göstergeleri olarak nükleer fragmentasyon ve yoğunlaşma, apoptotik veziküller ve kaspaz-3 aktivasyonu gözlenmiştir. Apoptoza neden olan bileşiklerin kanser tedavisinde önemli bir yeri olması göz önünde bulundurulduğunda, Anadolu'da bulu...

show abstract

Section: Discussionmentioning

confidence: 96%

In Vitro Cytotoxic and Proapoptotic Activities of Anatolian Macrovipera Lebetina Obtusa (Dwigubski, 1832) Crude Venom on Cultured K562 Human Chronic Myelogenous Leukemia Cells.

Süzergöz¹

2016

UHOD

View full text Add to dashboard Cite

show abstract

“…29,35,132 Third, early-stage cellular injury instead of cytotoxic antineoplastic potency could have been measured based upon either the detection of declines in cellular [H 3 ]-thymidine incorporation (proliferation analysis), or alterations in ATP utilization using an ATP-dependent assay methodology because each of these analysis methodologies is reportedly ‡ 10 · fold more sensitive in detecting early cell injury than MTT reagent based cell vitality assays. 133,134 Despite this consideration, assays that utilize MTT or similar cell vitality stain reagents for measuring cellular proliferation and growth continue to be extensively applied for the routine assessment of true chemotherapeutic cytotoxic anti-neoplastic potency. 7,26,30,[135][136][137][138][139] Fourth, cytotoxic anti-neoplastic potency could have been delineated in vivo against human neoplastic xenographs in animal hosts as a model for human neoplasia where the efficacy of a covalent immunochemotherapeutic frequently tends to be higher than in ex vivo tissue culture based models utilizing the same identical cancer cell type.…”

Section: Cytotoxic Anti-neoplastic Potencymentioning

confidence: 99%

Synthesis of a Covalent Epirubicin-(C₃-amide)-Anti-HER2/neuImmunochemotherapeutic Utilizing a UV-Photoactivated Anthracycline Intermediate

Coyne

Jones²,

Bear³

2012

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

The C 3 -monoamine on the carbohydrate moiety (daunosamine -NH 2 -3¢) of epirubicin was reacted under anhydrous conditions with succinimidyl 4,4-azipentanoate to create a covalent UV-photoactivated epirubicin-(C 3 -amide) intermediate with primary amine-reactive properties. A synthetic covalent bond between the UV-photoactivated epirubicin-(C 3 -amide) intermediate and the e-amine of lysine residues within the amino acid sequence of anti-HER2/neu monoclonal immunoglobulin was subsequently created by exposure to UV light (354 nm) for 15 minutes. Size-separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis combined with immunodetection analysis and chemiluminescent autoradiographic imaging revealed a lack of IgG-IgG polymerization or degradative protein fragmentation of the covalent epirubicin-(C 3 -amide)-[anti-HER2/neu] immunochemotherapeutic. Retained binding-avidity of epirubicin-(C 3 -amide)-[anti-HER2/neu] was validated by cell-ELISA utilizing monolayer populations of chemotherapeutic-resistant mammary adenocarcinoma SKBr-3 which highly overexpress membrane-associated HER2/neu complexes. Between epirubicin-equivalent concentrations of 10 -10 to 10 -6 M the covalent epirubicin-(C 3 -amide)-[anti-HER2/neu] immunochemotherapeutic consistently evoked levels of cytotoxic anti-neoplastic potency that were highly analogous to chemotherapeuticequivalent concentrations of epirubicin. Cytotoxic anti-neoplastic potency of epirubicin-(C 3 -amide)-[anti-HER2/ neu] against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3 challenged with epirubicin-(C 3 -amide)-[anti-HER2/neu] at an epirubicin-equivalent concentration of 10 -6 M was 88.5% (e.g., 11.5% residual survival). Between final epirubicin-equivalent concentrations of 10 -8 and 10 -7 M there was a marked threshold increase in the mean cytotoxic anti-neoplastic activity for epirubicin-(C 3 -amide)-[anti-HER2/neu] from 9.9% to 66.9% (90.2% to 33.1% residual survival).

show abstract

“…Time and dose of MTT solution in each experiment may be different for each cell or cell lines used (Sylvester, 2011). Importantly, chemotherapeutic agents and some drugs such as valproic acid can yield the lower results from the MTT assay (Ari et al, 2010;Ulukaya et al, 2008). The experimental procedure is as followed (Kummalue et al, 2005).…”

Section: Principle and Mechanism Of Actionmentioning

confidence: 99%

Experimental Therapeutics in Breast Cancer Cells

Jiratchariyakul¹,

Kummalue²

2011

Breast Cancer - Current and Alternative Therapeutic Modalities

View full text Add to dashboard Cite

The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested

Cited by 166 publications

References 27 publications

In Vitro Cytotoxic and Proapoptotic Activities of Anatolian Macrovipera Lebetina Obtusa (Dwigubski, 1832) Crude Venom on Cultured K562 Human Chronic Myelogenous Leukemia Cells.

In Vitro Cytotoxic and Proapoptotic Activities of Anatolian Macrovipera Lebetina Obtusa (Dwigubski, 1832) Crude Venom on Cultured K562 Human Chronic Myelogenous Leukemia Cells.

Synthesis of a Covalent Epirubicin-(C₃-amide)-Anti-HER2/neuImmunochemotherapeutic Utilizing a UV-Photoactivated Anthracycline Intermediate

Experimental Therapeutics in Breast Cancer Cells

Contact Info

Product

Resources

About

The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested

Cited by 166 publications

References 27 publications

In Vitro Cytotoxic and Proapoptotic Activities of Anatolian Macrovipera Lebetina Obtusa (Dwigubski, 1832) Crude Venom on Cultured K562 Human Chronic Myelogenous Leukemia Cells.

In Vitro Cytotoxic and Proapoptotic Activities of Anatolian Macrovipera Lebetina Obtusa (Dwigubski, 1832) Crude Venom on Cultured K562 Human Chronic Myelogenous Leukemia Cells.

Synthesis of a Covalent Epirubicin-(C3-amide)-Anti-HER2/neuImmunochemotherapeutic Utilizing a UV-Photoactivated Anthracycline Intermediate

Experimental Therapeutics in Breast Cancer Cells

Contact Info

Product

Resources

About

Synthesis of a Covalent Epirubicin-(C₃-amide)-Anti-HER2/neuImmunochemotherapeutic Utilizing a UV-Photoactivated Anthracycline Intermediate